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The ribosomal stalk protein P0 is involved in the susceptibility to the antifungal sordarin derivatives, as
reported for a number of Saccharomyces cerevisiae resistant mutants. Mammals and some lower eukaryotes are
naturally resistant to these compounds. It is shown here that expression in S. cerevisiae of the ribosomal protein
P0 from Homo sapiens and from other sordarin-resistant organisms results in a decrease in the sensitivity of
the cells to an agent of this class. To further characterize the P0 region responsible for inducing sordarin
resistance, a series of protein chimeras containing complementary regions of the human and yeast P0 proteins
were constructed and expressed in yeast. The chimeras complement the absence of the native yeast P0 except
in chimeras containing the human P0 carboxyl-terminal domain. Resistance to sordarins was found to be
associated with the presence of an HsP0 amino acid sequence comprising P118 to F138, which unexpectedly led
to higher resistance than the presence of the complete human P0. A comparison of the corresponding region
in P0 from yeast and sordarin-insensitive organisms, followed by site-directed mutagenesis, indicates that
residues in positions 119, 124, and 126 have an important role in determining resistance to sordarins.
Moreover, since sordarins block the eukaryotic elongation factor 2 (EF2) function, the P0 region affecting
sordarin susceptibility must correspond to EF2-interacting domains of the ribosomal stalk protein, which
affects the drug-binding site in the elongation factor.
Antibiotics, in addition to their primary interest as thera-
peutic agents, have been very useful as tools for investigating
their target cellular processes. One of the most fruitful exam-
ples is probably translation. From very early on, work on the
mode of action of protein synthesis inhibitors, such as strep-
tomycin, chloramphenicol, erythromycin, etc., has been closely
bound to the investigation into the bacterial translation ma-
chinery components, notably, ribosome structure and function
(8, 22).
Our understanding of the eukaryotic ribosome falls consid-
erably behind present knowledge of the prokaryotic particle
and, although many findings can probably be extended to all
kingdoms, there are a number of functional and structural
features specific to eukaryotic systems. One of them is the
ribosomal stalk, which has evolved into a much more complex
structure suited to performing additional functional roles (1).
A series of new compounds derived from sordarin were
described not long ago as potentially useful antifungals. The
sordarin derivatives apparently block the interaction of the
elongation factor in the ribosome (2, 11) in a way similar to but
distinguishable from fusidic acid (4). In agreement with this
mode of action, a drug-binding site has been recently located in
a yeast eukaryotic elongation factor 2 (EF2)-sordarin crystal
structure (10) in a previously proposed position based on the
mapping of sordarin resistance mutations in the elongation
factor modeled structure (2).
The ribosome, and more specifically the ribosomal stalk,
also has a role in determining the drug-inhibitory action, since
mutations in protein P0, one of the ribosomal stalk compo-
nents, also induce resistance to sordarins in S. cerevisiae (9, 12).
Moreover, the affinity of sordarin for the free EF2 is much
lower than for the ribosome-bound factor (6), confirming a
direct or indirect effect of the ribosome in the drug-binding
site. In addition, the stalk proteins P1 and P2 affect the
sordarin sensitivity of the yeast cells (9).
One of the most interesting peculiarities of these com-
pounds is their exceptional specificity. They only inhibit trans-
lation in some lower eukaryotes, including different yeast and
fungal species, but not in mammals (5); this specificity is ob-
viously the basis for their antifungal activity. It is, indeed,
surprising that the sordarin derivatives are able to differentiate
the translocation step in different eukaryotes in such a specific
way by interacting with highly conserved components, such as
EF2 and the ribosomal stalk P0 protein. Both EF2 and the
ribosomal stalk probably contribute to the specificity of the
sordarin action.
It has been generally assumed that stalk P proteins interact
with the elongation factor through their C-terminal peptide,
EESDDDMGFGLFD, which is identical in all of them and
forms the exposed stalk tip. Recently, this interaction was
experimentally proved by the two-hybrid method (13). How-
ever, since the stalk protein C end is identical in yeast and
humans, it is highly improbable that this interaction is the basis
of the differential effects of the drug. There must be other
stalk-EF2 interactions contributing to the specificity of sorda-
rin activity. Thus, protein P0 mutations inducing resistance to
sordarins in yeast have been mapped at around position 140 in
the 312-amino-acid P0 (9, 12). These data suggest that this part
of P0 can be involved in interactions with the elongation fac-
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tors and might correspond to some of the regions in the base
of the stalk that have been shown to be in contact with the
bound EF2 in cryoelectron microscopy reconstructed images
(20).
Determination of whether protein P0 is implicated in the
sordarin resistance of human cells and, if so, identification of
the responsible protein domain would provide information for
a better understanding of the mechanism responsible for the
specificity of sordarin antifungals and also for a more precise
characterization of the stalk-EF2 interactions. This informa-
tion may be useful for designing new more efficient and specific
antifungals.
MATERIALS AND METHODS
Yeast strains and growth media. S. cerevisiae W303-1b (MAT leu2-3,112
ura3-1 trp1-1 his3-11,15 ade2-1 can1-100) was used as a wild-type control strain.
S. cerevisiae W303dGP0 (MAT leu2-3,112 ura3-1 trp1-1 his3-11,15 ade2-1 can1-
100 RPP0::URA3-GAL1-RPP0) was derived from W303-1b as previously de-
scribed (18). Yeast strains were grown at 30°C in YEP medium (1% yeast extract
and 2% peptone) with either 2% glucose or 2% galactose as a carbon source.
Estimation of growth inhibition. Cells were grown at 30°C in multiwell plastic
plates containing 100 l of YEP-glucose medium per well and the indicated
concentration of inhibitor. Plates were placed in closed boxes over wet filter
paper pads to avoid dryness. After incubation from 24 h to 72 h, depending on
the strain growth rate, plates were shaken, and the A595 was estimated in a
microplate automatic reader (Bio-Rad model 550). The optical density of cells
growing exponentially in the absence of inhibitor, which was in the linear range
of the reader, was considered as 100% growth.
Isolation and analysis of ribosomes. Cells grown to an A600 of 1.0 were
resuspended in ice-cold buffer 1 (10 mM Tris-HCl [pH 7.4], 20 mM KCl, 12.5
mM MgCl2, 5 mM -mercaptoethanol) containing a protease inhibitor cocktail
(aprotinin, leupeptin, pepstatin, and phenylmethylsulfonyl fluoride at a 10-g/ml
final concentration) and broken by shaking them with glass beads in a FastPrep
FP120 (Bio 101/Savant) at 4°C in the cold room. The S30 fraction was obtained
by centrifuging the extract at 13,000 rpm for 20 min at 4°C in a Sorvall SS-30
rotor. Ribosomes were prepared from the S30 fraction by centrifugation at 4°C
in a TL100.3 rotor for 90 min at 90,000 rpm at 4°C. The particles were washed
by centrifugation under the same conditions in 20 mM Tris-HCl (pH 7.4), 500
mM ammonium acetate, 100 mM MgCl2, and 5 mM -mercaptoethanol. Ribo-
somes were finally stored at70°C in buffer 1. Ribosomal proteins were analyzed
by either sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) or isoelectrofocusing in a 2.0 to 5.0 pH range as indicated in previous
reports (24). Western blots were performed by using Immobilon-P membranes
(21). The specific antibodies to stalk proteins used in the present study were
described in previous publications (17, 23).
Enzymes and reagents. Restriction endonucleases were purchased from
Roche, MBI Fermentas, New England Biolabs, and Amersham and were used as
recommended by the suppliers. T4 DNA ligase, calf intestinal alkaline phospha-
tase, and the DNA polymerase I Klenow fragment were from Roche. DNA
manipulations were performed basically as described previously (16). PCR was
carried out by using Pfu DNA polymerase (Stratagene) and custom-made oligo-
nucleotides from Isogen, according to the recommendations of Dieffenbach and
Dveksler (3).
Sordarin derivative GM193663 (2) was kindly provided by GlaxoSmithKline
(Tres Cantos, Madrid, Spain).
Plasmids. pFL37-HsP0. Plasmid pBSP0, containing the complete S. cerevisiae
RPP0 gene was previously constructed (18). Plasmid pBSP0(Nd) derives from
pBSP0 by mutagenesis of the region immediately upstream of the initiator ATG
to generate an NdeI site (18). A fragment containing the coding region of human
RPP0 was amplified with Pfu DNA polymerase, with plasmid pT7P0 as a tem-
plate (14) and custom-made oligonucleotides (Table 1), creating an NdeI site at
the initiator ATG and an NheI site at the stop codon. This fragment was cloned
between the NdeI and NheI sites of plasmid pBSP0(Nd), generating plasmid
pBSHsP0. The EcoRI-XhoI fragment encoding the human P0 under the control
of the 5 and 3 regions of the yeast P0 was then cloned between the EcoRI-SalI
sites of pFL37 (15), thus yielding plasmid pFL37-HsP0. A similar strategy was
used to obtain pFL37-ScP0 (15).
pFL37-HsP0P1 and pFL37-HsP0P2. First, human RPP1 and RPP2 coding
regions were amplified from plasmids pT7P1 and pT7P2 (14) generating new
NdeI sites in the ATG and stop codons with oligonucleotides in Table 1. The 5-
and 3-flanking regions of yeast RPP1A gene were then amplified from BS-L47
(24) with custom oligonucleotides (Table 1) and the universal and reverse prim-
ers to create NdeI sites at the initiator and stop codons. Both fragments were
afterward subcloned at the appropriate restriction sites in Bluescript originating
pBS5.3YP1. The NdeI site joining the two yeast P1 flanking fragments in
pBS5.3YP1 was used to clone the human RPP1 and RPP2 genes. After diges-
tion with EcoRI and BamHI and treatment with Klenow, these constructions
TABLE 1. Oligonucleotides used to prepare the different constructs
Oligonucleotide Sequence Construct
NdeIH 5D 5-CACCGCCCATATGCCCAGGGAAG-3 HsP0
NheIH 3D 5-CCCCAAAGAAGCTAGCCTTTATTTCC-3 HsP0
OLP1ASC3 5-CTCTTTTATCATATGCCGCACTGT-3 BS5.3YP1
OLP1ASC5 5-GACAGAGGCCATATGTTCTTGTTA-3 BS5.3YP1
OLP1HSAE 5-TAACAAGAACATATGGCCTCTGTC-3 HsP1
OLP1HSEA 5-ACAGTGCGGCATATGATAAAAGAG-3 HsP1
OLP2HSAE 5-TCAACAACACATATGCGCTACGTC-3 HsP2
OLP2HSEA 5-TATTAATTACATATGTTTAATCAA-3 HsP2
OL2-3SCATGEND 5-ACCTCCTTTTTCCAAGCTTTGGGT-3 P0 HYY
OL2-3HSENDATG 5-ACCCAAAGCTTGGAAAAAGGAGGT-3 P0 HYY
OL2-3HSATGEND 5-ACTTCTTTCTTCCAGGCTTTAGGT-3 P0 YHH
OL2-3SCENDATG 5-ACCTAAAGCCTGGAAGAAAGAAGT-3 P0 YHH
OLI1QUI 5-GACCTCACTGAGATCAAGAACGTT-3 P0 55hYYY
OLI3QUI 5-AACGTTCTTGATCTCAGTGAGGTC-3 P0 55hYYY
OLI2QUI 5-GTGGTGCTGATGGGTAAGAACACC-3 P0 98hYYY
OLI4QUI 5-GGTGTTCTTACCCATCAGCACCAC-3 P0 98hYYY
OHS60 5-TTGCCAGACTTCGAGAAACTGCTG-3 P0 Yh60YY
OSC60 5-CAGCAGTTTCTCGAAGTCTGGCAA-3 P0 Yh60YY
OHS40 5-CCATTGACTGAAATCAGGGACATG-3 P0 Yh40YY
OSC40 5-CATGTCCCTGATTTCAGTCAATGG-3 P0Yh40YY
OHS20 5-GGTGCCGTTGCTCCATGTGAAGTC-3 P0Yh20YY
OSC20 5-GACTTCACATGGAGCAACGGCACC-3 P0Yh20YY
P0Hs3M1-fixed 5-GTTGACGGCTCTCACAGTGACTTCTTCTGGAGCAACGGCACCAGCTCT-3 P0Yh20***YY
P0Hs3M2 5-CCAGAAGAAGTCACTGTGAGAGCCGTCAACACTGGTCTCGGGCCC-3 P0Yh20***YY
P0atgNde 5-GTCATATGGAAGGCATTCGTGAAAAG-3 P0Yh20***YY
P0taaXho 5-GACTCGAGATCGAATAAACCGAAACCCATG-3 P0Yh20***YY
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were cloned in the EcoRI (Klenow-filled) site of pFL37-HsP0, thus generating
plasmids pFL37-HsP0P1 and pFL37-HsP0P2.
Protein P0 chimeras. Different plasmids expressing human-yeast RPP0 chime-
ras were created (Fig. 1). The amino, central, and carboxyl regions include res-
idues 1 to 136, 137 to 203, and 204 to 312, respectively (yeast P0 numbering). All
of them are derived from pBSP0(Nd) (here named pBSP0YYY) and pBSHsP0
(here pBSP0HHH). Two strategies were followed. Plasmids pBSP0HYY,
pBSP0YHH, pBSP055hYYY, pBSP098hYYY, pBSP0Yh60YY, pBSP0Yh40YY,
and pBSP0Yh20YY were obtained by overlapping PCR (3) with custom made
oligonucleotides (Table 1) and universal and reverse primers. Plasmids pBSP0YYH,
pBSP0HHY, pBSP0HYH, and pBSP0YHY were prepared by ligation of the
corresponding EcoRV fragments from human and yeast RPP0 genes, taking
advantage of an EcoRV site at an equivalent position in both genes. The
XhoI-EcoRI inserts of these constructions were subsequently cloned between
the SalI-EcoRI sites of pFL37, yielding the respective pFLP0 plasmid series,
ready to transform yeast strains. DNA sequencing confirmed all of the con-
structs.
Mutation of C119, P124, and R126 in the P0Yh20YY chimera. Site-directed
mutagenesis by overlapping PCR (3) was used to perform the changes C1193E,
P1243R, and Q1263V in the chimera P0Yh20YY. In a first step, two overlapping
DNA fragments containing the desired positions were amplified, with the pFL37-
Yh20YY plasmid as a template. The complementary oligonucleotides P0Hs3M1-
fixed and P0Hs3M2 were used as mutagenic primers at one end, and either
oligonucleotides P0atgNde or P0taaXho at the other end (Table 1). These frag-
ments were mixed and PCR amplified with the oligonucleotides P0atgNde and
P0taaXho as primers to obtain the complete coding region (0.95 kb) with the
desired nucleotide changes (P0Yh20***YY). This DNA fragment was digested
with NdeI and EcoRV and subcloned in pBSP0(Nd) previously digested with the
same enzymes, yielding pBS-P0Yh20***YY. This plasmid was then digested
with EcoRI and NotI, and the 2.5-kb DNA fragment containing the coding
region of the mutated chimera flanked by the S. cerevisiae RPP0 5 and 3
regulatory regions was cloned in pFL37-P0 digested with the same restriction
enzymes. The resulting pFL37-P0Yh20***YY plasmid, carrying the three mu-
tations simultaneously, was sequenced to confirm the presence of the desired
mutations.
Genetic manipulations and recombinant DNA techniques were carried out
according to standard methods as previously described (15).
RESULTS
Expression of H. sapiens P0 in S. cerevisiae W303dGP0. Plas-
mid pFL37-HsP0, containing the H. sapiens RPP0 gene encod-
ing ribosomal protein HsP0, was used to transform the condi-
tional P0 null mutant strains S. cerevisiae W303dGP0, derived
from wild-type W303-1b (18), yielding the transformed strain
W303dGP0-HsP0. As a control, the strain was also trans-
formed with pFL37-ScP0, which contained the yeast ScP0 pro-
tein. In strain W303dGP0 the chromosomal RPP0 gene is un-
der the control of the GAL1 promoter and, therefore, the cells
depend on the plasmid-encoded P0 protein to grow in glucose.
W303dGP0-HsP0 ribosomes were resolved by SDS-PAGE,
and proteins were detected by Western blotting with mono-
clonal antibody 3BH5, specific for the conserved C-terminal
peptide of all of the stalk components. The results showed a
reduction in the amount of 12-kDa acidic proteins when the
cells were grown in glucose to express HsP0 (Fig. 2A). Isoelec-
trofocusing of these proteins indicated that P2 and P1 were
preferentially reduced (Fig. 2B).
W303dGP0-HsP0 grows in the presence of glucose with a
doubling time of 170 min, which is about twofold higher than
the doubling time of W303dGP0-ScP0, the strain expressing
ScP0.
The effect of HsP0 expression on the sensitivity of the cells
to the sordarin derivative GM193663 was tested in liquid me-
dium. In addition to the control, W303dGP0-ScP0, strains
expressing P0 proteins from Dictyostelium discoideum, Rattus
norvegicus, and Aspergillus fumigatus, obtained previously (15),
were also included in the test as controls (Fig. 3). A clear in-
crease in the resistance of all of the strains expressing heter-
ologous proteins was found, which is higher in the case of cells
expressing fungal proteins in agreement with previous reports
(9, 19).
Effect of H. sapiens acidic P1 and P2 proteins on sordarin
activity. To test whether the presence of the human 12-kDa
stalk acidic proteins HsP1 and HsP2 have an effect on the HsP0-
induced sordarin resistance in S. cerevisiae, strain W303dGP0
was transformed with plasmids simultaneously containing the
human RPP0 gene and either human RPP1 or human RPP2.
In this way, strains W303dGP0-HsP0/P1 and W303dGP0-
HsP0/P2 were obtained, which showed doubling times in YEP-
glucose of 170 and 175 min, respectively, indicating that coex-
pression of a human acidic protein and HsP0 did not have a
significant effect on the growth rate in glucose of W303dGP0-
HsP0.
The presence of the heterologous acidic proteins in the
ribosomes from the transformed strains grown in glucose me-
dium was confirmed by Western analysis of SDS-PAGE gels.
In W303dGP0-derived strains, the total amount of acidic pro-
teins remains lower than in the controls, even when a human
acidic protein was expressed (data not shown).
The resistance to sordarin of the different strains also ex-
pressing one human acidic protein was not significantly differ-
ent from the resistance found in W303dGP0-HsP0 (data not
shown).
Mapping of the H. sapiens P0 domain conferring resistance
to S. cerevisiae. The ScP0 and HsP0 proteins have a consider-
able overall sequence similarity, although they also contain
domains with low homology (Fig. 4). To broadly define which
FIG. 1. Scheme of the protein P0 chimeras containing different
fragments of the human and yeast proteins. Numbers (except 1) indi-
cate the position of the carboxyl end of each fragment from S. cerevi-
siae P0 () and H. sapiens P0 () in each chimera. (A) Whole P0
protein chimeras; (B) amino-terminal domain chimeras.
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region in HsP0 is involved in conferring resistance to sordarins,
a series of protein chimeras were constructed in which the
amino, central, and carboxyl regions were exchanged between
HsP0 and ScP0 (Fig. 1A and Fig. 4). Plasmids containing the
corresponding chimerical genes were used to transform S. cer-
evisiae W303dGP0.
The different transformed strains were tested for growth in
glucose. The P0 chimeras were able to complement the ab-
sence of the native ScP0, except those containing the carboxyl
domain of the human P0. These exceptions were unexpected,
since W303dGP0 expressing the complete HsP0 was able to
grow in glucose. Since the promoter and flanking regions in all
of the constructs are identical, it is improbable that these
noncomplementing proteins are not expressed. These proteins
might be either inactive or degraded due to a wrong folding. In
general, the complementing chimeras have a rather small neg-
ative effect on cell growth (Table 2).
The transformed strains were tested for sensitivity to the
sordarin derivative GM193663 in glucose liquid medium. As
shown in Fig. 5, the strains expressing P0 chimeras that contain
the amino-terminal part of the human protein, HHY and
HYY, are approximately 1 order of magnitude more resistant
than either the control W303dGP0-ScP0 or the strain express-
ing the YHY chimera.
To define more accurately the region involved in sordarin
susceptibility, different fragments of the HsP0 amino-terminal
region were used to replace the equivalent fragments in the
yeast protein (Fig. 1B and Fig. 4). Two plasmids were con-
structed carrying a chimerical gene encoding a ScP0 con-
taining either the first 55 (pFL37-P0h55YYY) or the first 98
(pFL37-P0h98YYY) amino acids from HsP0. In addition,
plasmids pFL37-P0Yh60YY, pFL37-P0Yh40YY, and pFL37-
P0Yh20YY encoding ScP0s containing 60, 40, and 20 internal
amino acids, respectively, from HsP0 were also prepared. The
five constructs were used to transform W303dGP0. The trans-
formed strains did not show a significant alteration of the
growth rate in glucose medium (Table 2). An initial test
on agar plates indicated that strains transformed with the
ScP0 containing amino-terminal HsP0 amino acids (pFL37-
P0h55YYY and pFL37-P0h98YYY) showed susceptibilities
similar to that of the wild-type ScP0 (data not shown) and,
therefore, they were excluded from further analysis. The strains
expressing proteins P0Yh60YY, P0Yh40YY, and P0Yh20YY
were tested further in liquid medium and were found to display
a resistant phenotype equivalent to that displayed by cells ex-
pressing the P0HYY chimera (Fig. 6). Consequently, the re-
FIG. 2. Stalk proteins in ribosomes from cells expressing human protein P0. Ribosomes (30 g [A] and 300 g [B]) from yeast strain
W303dGP0 transformed with either pFL37-HsP0 (HsP0) or pFL37-ScP0 (ScP0) grown in YEP-glucose were resolved by SDS-PAGE (A) and
isoelectrofocusing in a 2.5 (bottom) to 5.0 (top) pH range (B). Proteins were detected by Western blotting with monoclonal 3BH5 in panel A and
by silver staining in panel B. The position of the different components is marked. In panel B, the lower bands correspond to the phosphorylated
form of each protein.
FIG. 3. Growth inhibition by increasing concentrations of sordarin
derivative GM193663 of S. cerevisiae W303dGP0 transformed with a
plasmid-expressing protein P0 from H. sapiens (F), S. cerevisiae (),
D. discoideum (), R. norvegicus (‚), and A. fumigatus (E). Inhibition
was estimated as indicated in Materials and Methods.
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sistance is associated with the HsP0 20-amino-acid region pres-
ent in P0Yh20YY.
Mutations in the HsP0 resistance domain increase sordarin
sensitivity. An amino acid sequence comparison of the sorda-
rin resistance domain of P0 proteins from S. cerevisiae and the
four resistant organisms tested thus far, namely, D. discoideum,
A. fumigatus, R. norvegicus, and H. sapiens, indicates quite a
few differences (Fig. 7). However, only four positions, 119, 121,
124, and 126 (based on the H. sapiens numbering) were con-
sistently different in the sensitive yeast protein and in the
proteins from the resistant species. In position 121 an isoleu-
cine in yeasts corresponds to valine in the resistant proteins,
which probably is structurally not very relevant. In contrast, the
differences in the other three positions were not conserved and
FIG. 4. Comparison of amino acid sequence of protein P0 from H. sapiens (H.s.) and S. cerevisiae (S.c.) by using the GAP program from GCG
(Wisconsin University Biotechnology Center). Solid arrowheads mark the limits of the amino, central, and carboxyl fragments included in the
protein chimera series described in Fig. 1A. Open arrowheads, followed by either a number or a “C” mark the amino terminus or the common
carboxyl terminus, respectively, of the HsP0 fragments in the P0YhnYY series (Fig. 1B). Similarly, open arrows mark the carboxyl ends (numbers)
and the common amino end (“A”) of the fragments in the P0hnYYY series (Fig. 1B).
FIG. 5. Growth inhibition of the different S. cerevisiae W303dGP0
glucose-viable strains expressing P0 chimeras with increasing concen-
trations of sordarin derivative GM193663 as estimated as in Fig. 2.
Cells expressing chimera are indicated as follows: HYY (), HHY
(‚), and YHY (E). The sordarin IC50s in cells expressing the wild-type
proteins from H. sapiens HHH (F) and S. cerevisiae () are included
as a reference.
TABLE 2. Effect of P0 chimeras on S. cerevisiae
W303dGP0 growtha
Transforming
plasmid
Doubling time
(min)
pFL37-P0 YYYb........................................................................... 90
pFL37-P0 HHHc .......................................................................... 170
pFL37-P0 YYH............................................................................ NGd
pFL37-P0 YHY............................................................................ 91
pFL37-P0 HYY............................................................................ 100
pFL37-P0 YHH............................................................................ NG
pFL37-P0 HYH............................................................................ NG
pFL37-P0 HHY............................................................................ 107
pFL37-P0h55YYY ....................................................................... 98
pFL37-P0h97YYY ....................................................................... 97
pFL37-P0Yh60YY ....................................................................... 98
pFL37-P0Yh40YY ....................................................................... 97
pFL37-P0Yh20YY ....................................................................... 96
a Growth in YEP-glucose medium.
b Equivalent to ScP0.
c Equivalent to HsP0.
d NG, no growth detected.
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might have an important role in determining the capacity of
the proteins to induce resistance to sordarins. To test this
possibility, Cys119, Pro124, and Gln126 were mutated to Glu,
Arg, and Val, respectively, which are the amino acids present
at the equivalent positions in ScP0. The P0Yh20***YY chi-
mera carrying the three mutations simultaneously was then
expressed in S. cerevisiae W303dGP0, and the strain was tested
for sordarin resistance in YEP-glucose medium containing
increasing concentrations of sordarin. The 50% inhibitory
concentration (IC50) of sordarin for the strain expressing
ScP0 was 0.05 g/ml, while the IC50 for the strain express-
ing the nonmutated chimera (P0Yh20YY) was 0.45 g/ml.
P0Yh20***YY, in contrast to the nonmutated chimera, had a
very small effect on the sordarin sensitivity of the yeast cells,
for which the IC50 was 0.09 g/ml.
DISCUSSION
The human ribosomal stalk HsP0 protein can be incorpo-
rated in the S. cerevisiae ribosome when expressed in a condi-
tional null mutant strain, W303dGP0, grown under restrictive
conditions. Ribosomes obtained from W303dGP0 cells ex-
pressing HsP0 contain this protein in roughly the same pro-
portion as the ScP0 present in control yeast ribosomes. In
contrast, the particles have a reduced amount of acidic 12-kDa
yeast proteins. In the ribosome, mainly proteins P1 and P2
are present and bind the heterologous HsP0 with higher affin-
ity than P1 and P2, suggesting that they are functionally
closer to the human P1 and P2. Confirming previous reports (7,
15), the results indicate that evolution has affected less the
interaction of P0 with rRNA than with the other stalk proteins.
The decrease in the 12-kDa protein content of the ribosome
may be, at least in part, responsible for the reduction in the
transformed strain growth rate. However, the additional ex-
pression of a human acidic protein, either HsP1 or HsP2, does
not substantially improve the complementing capacity of HsP0.
The presence of the HsP0 in the W303dGP0 ribosome re-
sults in an appreciable reduction in the sensitivity to sordarin
derivatives. A similar effect was detected by the expression of
P0 from other mammals, such as rat (RnP0), whereas the
proteins from two sordarin-insensitive fungi, such as D. discoi-
deum (DdP0) and A. fumigatus (AfP0), induce greater resis-
tance. The additional presence of human acidic proteins did
not have any detectable effect on resistance levels induced by
HsP0. These results confirm a direct participation of the stalk,
and particularly of protein P0, in the susceptibility to sordarins
previously reported for S. cerevisiae laboratory strains (9, 12).
The use of different P0 chimeras allows a sordarin resistance
domain to be defined; this domain comprises residues 118 to
138 in the HsP0 amino acid sequence and is directly respon-
sible for reducing sensitivity to the drug in S. cerevisiae. Muta-
tions inside this region have confirmed the involvement of
Cys119, Pro124, and Gln126 in the resistance mechanism. An
equivalent region has also been identified as being responsible
for the resistance to sordarins associated with protein P0 in
A. fumigatus (19), a naturally resistant fungus causing serious
nosocomial infections. This similarity indicates that the mech-
anism of resistance to sordarins is similar in mammals and
fungi as far as the participation of P0 is concerned. Surpris-
ingly, the yeast P0 containing this HsP0 fragment reduces the
susceptibility to sordarins more than the complete human pro-
tein does. This greater reduction is probably related to confor-
mational differences in this region when the proteins are as-
sembled into the ribosomal stalk. However, it is difficult to
definitely interpret the results without knowing the three-di-
mensional structure of the eukaryotic stalk.
Mutations have been mapped in S. cerevisiae P0, which also
defines a region around positions 135 and 145 related to sor-
darin susceptibility (9, 12). At this time it is difficult to conclude
whether this region and the one characterized here form a
unique site or whether they are independent sites. As indicated
previously, the three-dimensional structure of protein P0 has
not been resolved in any eukaryotic organism. Consequently, it
is difficult to draw a model for the specific role of each one of
FIG. 6. Sordarin sensitivity of S. cerevisiae W303dGP0 strains ex-
pressing P0YhnYY chimeras, i.e., P0Yh60YY (‚), P0Yh40YY (E),
and P0Yh20YY (). W303dGP0-ScP0 () was used as a control
strain. Growth inhibition was estimated as in Fig. 2.
FIG. 7. Comparison of the amino acid sequences of the protein P0 region involved in sordarin selectivity in S. cerevisiae (S.c.), H. sapiens (H.s.),
R. norvegicus (R.n.), A. fumigatus (A.f.), and D. discoideum (D.d.). Differences from yeast that are conserved among sordarin-resistant organisms
are indicated in boldface.
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the mentioned residues in the mechanism responsible for the
selectivity of these antifungal agents. However, it can be con-
cluded that this region must be closely related, probably in
direct contact, with EF2, the other sordarin sensitivity-deter-
mining component. Cryoelectron microscopic images of a S.
cerevisiae 80S ribosome-EF2-sordarin complex indicate a di-
rect interaction of the factor G domain with the stalk base,
probably protein P0 (20). It is quite probable that the interac-
tion site in P0 corresponds to the “sordarin sensitivity domain”
defined previously.
Interestingly, the sordarin-binding site has been located in a
pocket between domains III, IV, and V of EF2 in crystals of
free factor from S. cerevisiae (10), a finding in agreement with
most mapped resistance mutations (2, 11). This region is not
involved in interactions of the factor with the ribosome (20).
These results are, therefore, hardly compatible with a direct
participation of the ribosomal stalk in sordarin binding to its
target, and thus P0 must induce resistance through allosteric
effects. Interestingly, the P0 resistant mutations reduce the
sordarin-binding capacity of the EF2-ribosome complex from
20 to 50% (9). It is uncertain whether this reduction can ac-
count for the high-resistance phenotype of the mutant strains;
however, a long-distance effect of P0 mutations on the drug-
binding site is evident. In this sense, it must be taken into
account that the affinity of EF2 for sordarins increases dramat-
ically upon binding to the ribosome, implying important
changes in the drug-binding site, which can be at least partially
induced by interaction with protein P0. In agreement with this
proposal, a couple of EF2 resistance mutations have been
mapped in R180 and V187 at the G domain (11) in the stalk
interaction site. All of these mutations can affect the EF2
conformational change induced by P0 interaction in the drug-
binding site affecting the affinity and thus the activity of sor-
darins.
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